СОВРЕМЕННАЯ ФАРМАКОТЕРАПИЯ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
https://doi.org/10.15829/1560-4071-2017-7-171-177
Аннотация
Фармакотерапия остается доминирующим способом лечения больных с фибрилляцией предсердий (ФП). Ведение пациентов с ФП включает в себя решение о выборе между урежением частоты желудочковых сокращений и поддержанием синусового ритма. Во втором случае применяются антиаритмические препараты, выбор которых в первую очередь определяется соображениями безопасности и зависит от индивидуальных характеристик пациентов. В статье дана краткая характеристика эффективности и безопасности собственно антиаритмических и иных препаратов для поддержания синусового ритма у больных с ФП. Новые данные свидетельствуют о возможности снижения риска инсульта и смертности, прекращении антикоагулянтной терапии при более агрессивном поддержании синусового ритма.
Об авторах
С. Г. Канорский
ФГБОУ ВО Кубанский государственный медицинский университет Минздрава России
Россия
Канорский Сергей Григорьевич— доктор медицинских наук профессор, зав. кафедрой терапии № 2 ФПК и ППС
Россия
Канорский Сергей Григорьевич— доктор медицинских наук профессор, зав. кафедрой терапии № 2 ФПК и ППС
Ю. С. Коваленко
ФГБОУ ВО Кубанский государственный медицинский университет Минздрава России
Россия
Кандидат медицинских наук, ассистент кафедры эндокринологии ФПК и ППС и ППС
Россия
Кандидат медицинских наук, ассистент кафедры эндокринологии ФПК и ППС и ППС
Список литературы
1. Chugh SS, Havmoeller R, Narayanan K et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129:837-47.
2. Mozaffarian D, Benjamin EJ, Go AS et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016; 133: e38-360.
3. Schnabel RB, Yin X, Gona P et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015; 386:154-62.
4. Sanna T, Diener HC, Passman RS et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370:2478-86.
5. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37:2893-2962.
6. Andersson T, Magnuson A, Bryngelsson IL et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013; 34:1061-7.
7. Kanorskii SG. Modern drug therapy of atrial fibrillation: selection of treatment strategy, antiarrhythmic preparations, and schemes of treatment. Kardiologiia 2012; 9:58-63. Russian (Канорский С. Г. Современная медикаментозная терапия фибрилляции предсердий: выбор тактики, антиаритмических препаратов и схем лечения. Кардиология 2012; 9:58-63).
8. Kanorskii SG. Antiarrhythmic therapy in patients with paroxysmal and persistent atrial fibrillation: identification of achievable goals and assessment of available funds. Kardiologiya 2014; 2:70-4. Russian (Канорский С.Г. Антиаритмическая терапия у больных с пароксизмальной и персистирующей формами фибрилляции предсердий: определение достижимой цели и оценка имеющихся средств. Кардиология 2014; 2:70-4).
9. Kanorskii SG. Treatment of Patients With Atrial Fibrillation: the Search for Optimal Solutions. Kardiologiya 2016; 8:46-53. Russian (Канорский С. Г. Лечение больных с фибрилляцией предсердий: поиск оптимальных решений. Кардиология 2016; 8:46-53).
10. Nguyen T, Jolly U, Sidhu K et al. Atrial fibrillation management: evaluating rate vs rhythm control. Expert Rev Cardiovasc Ther 2016; 14:713-24.
11. Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013; 36:122-33.
12. Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 2012; 172:997-1004.
13. Halsey C, Chugh A. Rate Versus Rhythm Control for Atrial Fibrillation. Heart Fail Clin 2016; 12:193-203.
14. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109:1509-13.
15. Zimetbaum P. Is rate control or rhythm control preferable in patients with atrial fibrillation? An argument for maintenance of sinus rhythm in patients with atrial fibrillation. Circulation 2005; 111:3150-6.
16. Lip GY, Laroche C, Ioachim PM et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; 35:3365-76.
17. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199-267.
18. Gopinathannair R, Etheridge SP, Marchlinski FE et al. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol 2015; 66:1714-28.
19. Kotecha D, Manzano L, Krum H et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016; 353:i1855.
20. Kotecha D, Holmes J, Krum H et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384:2235-43.
21. Ulimoen SR, Enger S, Carlson J et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013; 111:225-30.
22. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129-200.
23. Ulimoen SR, Enger S, Pripp AH et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 2014; 35:517-24.
24. Whitbeck MG, Charnigo RJ, Khairy P et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J 2013; 34:1481-8.
25. Turakhia MP, Santangeli P, Winkelmayer WC et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 2014; 64:660-8.
26. Ziff OJ, Lane DA, Samra M et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351:h4451.
27. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-33. 2
28. Van Gelder IC, Wyse DG, Chandler ML et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006; 8:935-42.
29. Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362:1363-73.
30. Groenveld HF, Tijssen JG, Crijns HJ et al. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol 2013; 61:741-8.
31. Steinberg BA, Kim S, Thomas L et al. Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). J Am Heart Assoc 2015; 4:e002031.
32. Van Gelder IC, Rienstra M, Crijns HJ et al. Rate control in atrial fibrillation. Lancet 2016; 388:818-28.
33. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet 2016; 388:829-40.
34. Lafuente-Lafuente C, Valembois L, Bergmann JF et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015; 3:CD005049.
35. Anselmino M, Matta M, D’Ascenzo F et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014; 7:1011-8.
36. Kirchhof P, Breithardt G, Camm AJ et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J 2013; 166:442-8.
37. Zimetbaum P, Waks JW. Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation. J Cardiovasc Pharmacol Ther 2017; 22:3-19.
38. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321:406-12.
39. Hayward C, Patel HC, Patel K et al. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. Eur Heart J Cardiovasc Pharmacother 2016; 2:90-4.
40. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913-20.
41. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352:1861-72.
42. Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011; 13:329-45.
43. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009; 84:234-42.
44. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-37.
45. Danzi S, Klein I. Amiodarone-induced thyroid dysfunction. J Intensive Care Med 2015; 30:179-85.
46. Schweizer PA, Becker R, Katus HA et al. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. Drug Des Devel Ther 2011; 5:27-39.
47. Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987-99.
48. Le Heuzey JY, De Ferrari GM, Radzik D et al. A short-term, randomized, doubleblind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21:597-605.
49. Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668-78.
50. Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268-76.
Рецензия
Для цитирования:
Канорский С.Г., Коваленко Ю.С. СОВРЕМЕННАЯ ФАРМАКОТЕРАПИЯ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Российский кардиологический журнал. 2017;(7):171-177. https://doi.org/10.15829/1560-4071-2017-7-171-177
For citation:
Kanorsky S.G., Kovalenko Yu.S. STATE OF THE ART PHARMACOLOGICAL THERAPY FOR ATRIAL FIBRILLATION. Russian Journal of Cardiology. 2017;(7):171-177. (In Russ.) https://doi.org/10.15829/1560-4071-2017-7-171-177
Просмотров:
1027
Послать статью по эл. почте 